Phenylethyl Alcohol

Phenylethyl Alcohol

SCHEMBL908803

OCCc1ccccc1.[c]1ccccc1

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.73
CA2 P00918 2/20 0.44
TSHR P16473 1/20 0.44
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
CASP1 P29466 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CA1 P00915 1/20 0.41
KEAP1 Q14145 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP2A6 P11509 1/20 0.41
HTR2A P28223 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
LTA4H P09960 1/20 0.39
EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylethyl Alcohol SCHEMBL7240959 0.88 TDP1 (0.94) TDP1CA2TSHRCYP4F2CYP4A11
Phenylethyl Alcohol SCHEMBL9354513 0.85 TDP1 (0.89) TDP1CA2TSHRCYP4F2CYP4A11
Phenylethyl Alcohol SCHEMBL11450063 0.85 TDP1 (1.00) TDP1CA2TSHRCYP4F2CYP4A11
Phenylethyl Alcohol SCHEMBL1867158 0.85 TDP1 (1.00) TDP1CA2TSHRCYP4F2CYP4A11
Phenylethyl Alcohol SCHEMBL1838 0.85
Phenylethyl Alcohol SCHEMBL28820852 0.85 TDP1 (1.00) TDP1CA2TSHRCYP4F2CYP4A11
Phenylethyl Alcohol SCHEMBL8968173 0.85 TDP1 (1.00) TDP1CA2TSHRCYP4F2CYP4A11
Phenylethyl Alcohol SCHEMBL27927126 0.85 TDP1 (1.00) TDP1CA2TSHRCYP4F2CYP4A11
Phenylethyl Alcohol SCHEMBL5967453 0.83 TDP1 (0.94) TDP1CA2TSHRCYP4F2CYP4A11
Phenylethyl Alcohol SCHEMBL5946545 0.83 TDP1 (0.94) TDP1CA2TSHRCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160008322-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP (CA) 2016-01-14 US disclosed
US-20140314685-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2014-10-23 US disclosed
US-20130171077-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2013-07-04 US disclosed
US-8163938-B2 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2012-04-24 US disclosed
EP-1666459-B1 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP (CA) 2011-10-19 EP disclosed
US-8008342-B2 Ion channel modulating compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2011-08-30 US disclosed
US-20110207730-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2011-08-25 US disclosed
EP-2298735-A1 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2011-03-23 EP disclosed
US-7875611-B2 (+)-trans-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]; (1R,2R)/(1S,2S)-2-[1,4-dioxa-7-azaspiro[4.4]non-7-yl]-1-(1-naphthenethoxy)cyclohexanecyclohexane; treatment of arrhythmia and the production of analgesia and local anesthesia CARDIOME PHARMA CORP. (CA) 2011-01-25 US disclosed
US-20110004006-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2011-01-06 US disclosed
US-20060189677-A1 Treatment of arrhythmia and the production of analgesia and local anesthesia by administering 1-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(3-hydroxy-1-pyrrolidinyl)cyclohexane or a salt CARDIOME PHARMA CORP. (CA) 2006-08-24 US disclosed
EP-1666459-A2 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2006-06-07 EP disclosed
US-7057053-B2 for treatment of arrhythmia and the production of analgesia and local anesthesia CARDIOME PHARMA CORP. (CA) 2006-06-06 US disclosed
EP-1560812-B1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP (CA) 2006-05-10 EP disclosed
US-20050209307-A1 Cardiovascular disorders; antiarrhythmia agents as result od analgesics, anesthetics CARDIOME PHARMA CORP. (CA) 2005-09-22 US disclosed
US-20050192208-A2 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2005-09-01 US disclosed
US-20050020481-A1 Ion channel modulating compounds and uses thereof BAIN ALLAN I (CA) 2005-01-27 US disclosed
EP-1422217-A2 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2004-05-26 EP disclosed
EP-1087934-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF Nortran Pharmaceuticals Inc. (CA) 2001-04-04 EP disclosed
WO-1999050225-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC. (CA) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110004006-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF KCNH2, KCNC1, KCNH3 TDP1 1872/4885CA2 407/4885TSHR 3782/4885
US-20130171077-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 TDP1 4354/4885CA2 166/4885TSHR 2898/4885
US-20110207730-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 TDP1 4354/4885CA2 166/4885TSHR 2898/4885
US-20050020481-A1 Ion channel modulating compounds and uses thereof TRPV1, TRPA1, KCNN2 TDP1 4354/4885CA2 166/4885TSHR 2898/4885
US-20050209307-A1 Cardiovascular disorders; antiarrhythmia agents as result od analgesics, anesthetics KCNH1, TRPV1, KCNH2 TDP1 1189/4885CA2 221/4885TSHR 3313/4885
US-20160008322-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 TDP1 4354/4885CA2 166/4885TSHR 2898/4885
US-20140314685-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 TDP1 4354/4885CA2 166/4885TSHR 2898/4885
US-20060189677-A1 Treatment of arrhythmia and the production of analgesia and local anesthesia by administering 1-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(3-hydroxy-1-pyrrolidinyl)cyclohexane or a salt KCNN2, KCNN3, KCNN1 TDP1 2955/4885CA2 124/4885TSHR 2369/4885
US-20050192208-A2 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 TDP1 3829/4885CA2 169/4885TSHR 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.